Alpha Cognition rises on commercial launch of Alzheimer's drug

Alpha Cognition

18/03/2025 13:45

** Drug developer Alpha Cognition ACOG.O rises 12.5% to $5.91

** ACOG says it has launched its oral therapy, Zunveyl, commercially to treat mild to moderate Alzheimer's disease (AD)

** Alzheimer's is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to do simple tasks, which is the most common form of dementia affecting nearly 7 million people

** Co says patients can now access the drug in 5 milligram (mg), 10 mg and 15 mg doses

** Zunveyl was approved by the FDA to treat AD in July 2024

** Brokerage H.C. Wainwright estimates Zunveyl to generate $540 millon in peak annual sales in the US by the late 2030s

** As of last close, ACOG down ~65% in the past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))